NCT06100328|Recruiting
Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE)
UNIQUE
Loading search results
UNIQUE
Sponsor study identifier
observational
40
1 country
1
Study Start
October 26, 2023
Actual (reported)Primary Completion
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study aims to retrospectively and prospectively collect clinical and biological specimen data from patients with cardiac tumors who meet the inclusion and exclusion criteria. Various techniques, including general molecular biology analysis and multi-omics analysis, will be used to construct a prognostic model for cardiac tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 6, 2023
Actual (reported)October 25, 2023
Actual (reported)October 26, 2023
Actual (reported)July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in the incidence of MACCE
MACCE (major adverse cardiac and cerebrovascular events) including all-cause death, myocardial infarction, coronary revascularization surgery and stroke. The MACCE will be assessed from the medical records.
1, 3, 6, 12, 24, 36, 48, and 60 months after enrollment.
Change in the incidence of all-cause death
1, 3, 6, 12, 24, 36, 48, and 60 months after enrollment.
Change in the incidence of myocardial infarction
1, 3, 6, 12, 24, 36, 48, and 60 months after enrollment.
Change in the incidence of coronary revascularization surgery
1, 3, 6, 12, 24, 36, 48, and 60 months after enrollment.
Change in the incidence of stroke
1, 3, 6, 12, 24, 36, 48, and 60 months after enrollment.
patients who are diagnosed as cardiac myxoma
patients who are diagnosed as cardiac fibroma
patients who are diagnosed as cardiac lipoma
patients who are diagnosed as cardiac hemangioma
patients who are diagnosed as cardiac malignant tumor
All patients must meet at least one of the following diagnostic criteria for cardiac neoplasms: 1. Cardiac myxoma group; 2. Cardiac fibroma group; 3. Cardiac lipoma group; 4. Cardiac hemangioma group; 5. Cardiac undifferentiated sarcoma; 6. Cardiac angiosarcoma group; 7. Cardiac rhabdomyosarcoma group; 8. Cardiac lymphoma group; 9. Cardiac metastasis group; 10. Other cardiac tumors group.
First Affiliated Hospital of Xi'an Jiantong University
Xi'an, Shaanxi, 710061, China
Guoliang Li
First Affiliated Hospital Xi'an Jiaotong University
Yang Yan
First Affiliated Hospital Xi'an Jiaotong University
First Submitted
July 6, 2023
First Posted
October 25, 2023
Study Start
October 26, 2023
Actual (reported)Primary Completion
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Clinical Study of Endocardial Myocardial Biopsy
Contact the study team to confirm eligibility.
Study Completion
July 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 12, 2024
Record last verified: 2024-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: